Tirzepatide
LY3298176
Tirzepatide is a synthetic peptide studied in in-vitro and preclinical research as a dual agonist of the GLP-1 and GIP receptors. Research reagent only — not for human consumption or medical use.
Key facts
- Class
- Dual incretin agonist
- Targets
- GLP-1 / GIP
- Form
- Lyophilised (powder)
- Status
- Research Use Only
Study library
All results on PubMedSemaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
Rodriguez PJ, et al. · JAMA internal medicine · 2024
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Look M, et al. · Diabetes, obesity & metabolism · 2025
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, et al. · The New England journal of medicine · 2025
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, et al. · The New England journal of medicine · 2025
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
Zhao L, et al. · JAMA · 2024
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Loomba R, et al. · The New England journal of medicine · 2024
Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).
Wilson L, et al. · Diabetes, obesity & metabolism · 2026
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Rosenstock J, et al. · Lancet (London, England) · 2021
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Zeng Q, et al. · Frontiers in endocrinology · 2023
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.
Chuang MH, et al. · JAMA network open · 2024
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS, et al. · JCI insight · 2020
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B, et al. · Lancet (London, England) · 2021
Results retrieved live from PubMed (NCBI). Research literature only — no medical advice.
Research peptides — Research Use Only
- Not for human consumption
- Not for the diagnosis, treatment or prevention of any disease